Dreamfold

Dreamfold is transforming drug discovery by applying generative machine learning to explore the protein universe and unlock new treatments.

Dreamfold is transforming drug discovery by applying generative machine learning to explore the protein universe and unlock new treatments.
AI technology
Milestones
Investment year
Investment stage
Investment status
Deal team
Tom Henriksson
Dreamfold is transforming drug discovery by applying generative machine learning to explore the protein universe and unlock new treatments.

Dreamfold is pioneering generative machine learning techniques to navigate the vast landscape of proteins, with the goal of discovering breakthrough medicines. Their work lies at the intersection of machine learning, molecular simulation, and synthetic biology. Founded by researchers from Yoshua Bengio’s lab alongside Michael Bronstein, a leading AI professor at the University of Oxford, Dreamfold is driven by a mission to bring hope to millions of patients who currently have no cure.

News highlights

All news
6
min read

Why we invested in Ubitium

OpenOcean has invested $4 million in Ubitium’s $14 million seed round, led by US-based Ibex Investors with participation from Quantum Systems co-founder Florian Seibel and existing backers KBC Focus Fund, Runa Capital, and Inflection.
6
min read

IQM's dual listing is a blueprint for European deep tech

In July IQM Quantum Computers started trading on Nasdaq New York and Nasdaq Helsinki, on subsequent days.
8
min read

Three things the State of Quantum 2026 report tells an early-stage investor

The State of Quantum 2026 report shows quantum computing maturing into a real market. For investors, the biggest opportunities lie in enabling infrastructure today and commercial adoption tomorrow.
Tom Henriksson
Tom Henriksson
General Partner
Tom Henriksson
Tom Henriksson
General Partner
AI technology
AI technology